Kennedy’s vaccine overhaul turns public-health uncertainty into commercial risk
Robert F. Kennedy Jr has wound down federal mRNA vaccine development, tightened access to COVID shots and cut vaccines for six of 17 diseases from the childhood immunisation schedule — a change a federal judge has since blocked, in a ruling that also found his replacement vaccine advisory board unlawfully constituted.
The federal schedule guides state mandates, insurance coverage and manufacturers’ protection from ordinary civil claims, so weakening it can simultaneously reduce insured demand for affected vaccines and expose producers to the direct litigation that the Vaccine Injury Compensation Program was designed to contain.
If courts ultimately allow vaccines to leave the federal schedule, manufacturers could face greater exposure to direct civil litigation alongside lower uptake, disrupted research funding and higher compliance costs, while specialist claimant firms would stand to benefit if more disputes move into the courts or the federal compensation scheme expands.
The wider consequence is a fragmented American vaccine market in which recommendations diverge across federal agencies, states, insurers and medical bodies, forcing providers and manufacturers to spend more on compliance and risk management while preventable outbreaks push additional costs onto hospitals, employers and public budgets.